Compare PDS & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | TRVI |
|---|---|---|
| Founded | 1951 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1998 | 2019 |
| Metric | PDS | TRVI |
|---|---|---|
| Price | $92.57 | $13.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $122.33 | $21.55 |
| AVG Volume (30 Days) | 81.6K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.00 | $5.41 |
| 52 Week High | $103.80 | $16.12 |
| Indicator | PDS | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 43.10 |
| Support Level | $88.08 | $13.12 |
| Resistance Level | $102.75 | $13.55 |
| Average True Range (ATR) | 3.76 | 0.57 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 31.32 | 15.34 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.